4 January 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that it has signed a collaboration agreement with a US-based biopharmaceutical company to explore the use of the Company’s exosome technology platform as a potential delivery vehicle for synthetic oligonucleotides used in gene therapy.

Read more…

 

 

Back